JITC's Reading List

The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Clinical/Translational Cancer Immunotherapy co-Section Editor Dr. Jason Luke . “Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer” by Memon et al Cancer Cell (2024) Summary: Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about ...
0 comments
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Case Reports Section Editor Dr. Sebastian Kobold. “T-cell Lymphoma and Secondary Primary Malignancy Risk After Commercial CAR T-cell Therapy” by Ghilardi et al Nat Med (2024) Abstract: We report a T-cell lymphoma (TCL) occurring three months after anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy for non-Hodgkin ...
0 comments
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Guidelines and Consensus Statements Section Editor Dr. Robert L. Ferris . “Lung tumor–infiltrating Treg have divergent transcriptional profiles and function linked to checkpoint blockade response” by Dykema et al Sci Immunol . (2023) Abstract : Regulatory T cells (T reg ) are conventionally viewed as suppressors ...
0 comments
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Immunotherapy Biomarker's co-Section Editor Dr. Alexandra Synder . “The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients” by Freidrich et al Cancer Cell (2023) Abstract : Bispecific T cell engagers (TCEs) have shown promise in the treatment of various ...
0 comments
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Social Media Editor Dr. Praveen Bommareddy . Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial by Routy et al Nature Medicine (2023) Combination therapy with immune checkpoint inhibitors has revolutionized treatment for melanoma, but there is still a significant ...
0 comments
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Social Media Editor Dr. Kristin Anderson . “An oncolytic virus–delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment” by DePeaux et al J Exp Med (2023) Abstract : While checkpoint blockade immunotherapies have widespread success, they rely on a responsive immune infiltrate; as such, treatments ...
0 comments
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Interim Editor-in-Chief Dr. James L. Gulley . “Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma A Meta-Analysis” by Serritella et al JAMA Oncol. (2023) Abstract: Importance – Although the combination of nivolumab plus ipilimumab has unquestionable benefit over nivolumab monotherapy ...
0 comments
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Basic Tumor Immunology co-Section Editor Dr. Eric Tartour . “CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers” by Bill et al Science (2023) Abstract: Tumor microenvironments (TMEs) influence cancer progression but are complex and often differ between patients. Considering ...
0 comments
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Reviews co-Section Editor Dr. Sandra Demaria . “The PD-L1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in HNSCC” by Nieto et al J Natl Cancer Inst. (2023) Abstract: The programmed death receptor 1 (PD-1) and ligand (PD-L1) are validated cancer ...
0 comments
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Clinical/Translation co-Section Editor Dr. Douglas McNeel . “Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance” by Dhivya Sridaran et al Nat Commun . (2022) Abstract: Solid tumours are highly refractory to immune checkpoint blockade (ICB) therapies ...
0 comments
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Immunotherapy Biomarkers co-Section Editor Dr. Ignacio Melero . “Antibodies against endogenous retroviruses promote lung cancer immunotherapy” by Kevin W Ng et al Nature (2023) Abstract: B cells are frequently found in the margins of solid tumours as organized follicles in ectopic lymphoid organs called tertiary lymphoid ...
0 comments
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Interim Deputy Editor-in-Chief Dr. Sjoerd H. van der Burg. “Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction” by Jingya Qiu et al Nature Cancer (2023) Loss of interferon gamma (IFNy) signaling is a canonical mechanism of resistance to PD-1 ...
0 comments
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Commentary/Editorials Section Editor Dr. Christian Capitini . “T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis” by Daria Briukhovetska et al Immunity (2023) IL-22-producing helper (T h ) cells are associated with poor prognosis in breast and lung ...
0 comments
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Basic Tumor Immunology co-Section Editor Dr. Cornelis J.M. Melief . “Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma” by Jason A. Chesney et al JCO (2023) Jason A. Chesney et al report a phase III, double-blinded, ...
0 comments
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Case Reports Section Editor Dr. Sebastian Kobold. JITC’S READING LIST SUMMARIES – JANUARY 2023 “Glofitamab for relapsed or refractory diffuse large B cell lymphoma” by Michael J Dickinson et al NEJM (2022) Prognosis is poor for patients with diffuse large B cell lymphoma (DLBCL) who have received at least two prior lines ...
0 comments
This month's featured editor is Dr. Robert L. Ferris, Section Editor for the Guidelines and Consensus Statements section. “LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation” by Clifford Guy et al Nat Immunol (2022) The mechanism by which LAG3 inhibits T cell-mediated anti-cancer immunity is not well understood. Through elegant biophysical experiments, Clifford Guy et al ...
0 comments
This month's featured editor is a JITC Social Media Editor, Dr. Praveen K. Bommareddy. “ Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq Trial – ECOG-ACRIN EA6134” by Michael B. Atkins et al J Clin Oncol (2022) Two highly effective first-line combination therapies are available for patients with BRAF V600-mutated melanoma: targeted therapy ...
0 comments
This month's featured editor is Dr. Pedro J. Romero, Editor-in-Chief. “PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells” by Laura Codarri Deak et al Nature (2022) Interleukin (IL)-2 is an essential cytokine and growth factor for T cell expansion and differentiation. While IL-2 has been utilized as a cancer immunotherapy, the presence of the alpha chain of the IL-2 receptor (IL-2R-α, CD25) on non-tumor ...
0 comments
This month's featured editor is Dr. James Gulley, JITC Deputy Editor-in-Chief. “PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer” by Andrea Cercek et al NEJM (2022) Mismatch repair deficient (dMMR) colorectal cancer is responsive to anti-PD-1-based immune checkpoint inhibition (ICI) in the metastatic setting, and Andrea Cercek and colleagues hypothesized that treatment with the anti-PD-1 monoclonal antibody ...
0 comments
This month's featured editor is Dr. Matthew Hellmann, Deputy Editor for the Case Reports section. “PEMBROLIZUMAB PLUS CHEMOTHERAPY IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER” by Javier Cortes et al NEJM (2022) The previously published results of the protocol-specified second interim analysis of the phase III, randomized, double-blind, international trial KEYNOTE-355 demonstrated that the addition of pembrolizumab to chemotherapy ...
0 comments